

SPOEX

Yfirferð á vinnu SPOEX

Drífa Ósk Sumarliðadóttir
29. október 2024



2023



09:02

📶 📶 🔋 100

SPOEX

FÉLAGSSKÍRTEINI
31.05.25

SPOEX

SAMTÖK PSORIASIS-
OG EXEMSJÚKLINGA

NAFN

Drífa Ósk Sumarliðadóttir

KENNITALA

0670760639



10:09

📶 📶 🔋

SPOEX

FÉLAGSSKÍRTEINI
31.05.24



Samtök psoriasis- og exemsjúklinga

NAFN

Drífa Ósk Sumarliðadóttir

KENNITALA

0670760639



Samtök psoriasis- og exemsjúklinga



Göngudeildin

Spoex rekur öfluga göngudeild.

Skrá á póstlista

Viltu fá regluleg fréttabréf frá okkur?

Ganga í félagið

Viltu taka þátt í starfinu með okkur?

Vefverslun

Smyrsi?





Nordpsö

the existing evidence and data across the countries in a Nordic White Paper on Climate Therapy for Psoriasis Patients.

This purpose of the white paper is to constitute a platform for the member associations in Nord-Pso to create awareness on the need for therapy treatment for psoriasis patients now and in the future, and act as a tool for engaging decision makers, political and clinical stakeholders in this agenda.

To support this purpose the Nordic white paper should provide an overview of the existing evidence for climate therapy treatment, give an overview of the current situations of the accessibility in the six member countries as well as appoint the main improvement areas moving forward.

Content and activities

In order to create a white paper that gathers accessible, relevant knowledge in the field, points out possible improvement areas and at the same time presents it in a format that

:R	Gothenburg Göteborgsgatan 7	Stockholm Klarabergsgatan 60, 1tr	Copenhagen Ved Stranden 16, 2. Sal	Oslo Kronprinsens gate 1	Helsinki Uudenmaankatu 7	Tallinn Vara-Viru 3	Brussels Avenue Marnix 28
	SE-411 34 Gothenburg Sweden	SE-111 21 Stockholm Sweden	DK-1061 Copenhagen K Denmark	NO-0251 Oslo Norway	FI-00130 Helsinki Finland	10111, Tallinn Estonia	1000 Brussels Belgium
www.rudpetersen.com info@rudpetersen.com							



**Rud Pedersen
Public Affairs**

can engage key stakeholders, Rud Pedersen suggests that it is developed in close collaboration with the patient associations and is further qualified by involving key clinicians so they can contribute with relevant content and support the final outcome.

Rud Pedersen suggests the following activities:

1. Development of a synopsis/outline that provides an overview of the structure and content of the white paper
2. Collect relevant materials from the patient associations on the treatment situation as well as figures data and facts from all the six countries to support and consolidate the statements in the paper (sent by the six patient associations to RP)
3. Execute a (virtual) workshop with the project group (one representative from each country), where the biggest challenges and opportunities for improvement are discussed
4. Identify and prioritize 1-2 key clinicians who can contribute to the White Paper and ensure the quality of presented evidence
5. Gather all inputs from the workshop, the project group and the clinicians and draft








SPOEX

- Erum alltaf að reyna að bæta okkur
- Viljum nána samvinnu við húðsjúkdómalækna
- Fræðslu fyrir félagsmenn
- Styrkir



Stjórn SPOEX

- Ingvar Ágúst Ingvarsson – formaður SPOEX
- Arnþór Jón Egilsson – varaformaður SPOEX
- Elín Helga Hauksdóttir – gjaldkeri SPOEX
- Drífa Ósk Sumarliðadóttir – aðalmaður í stjórn
- Valgerður Auðunsdóttir – aðalmaður í stjórn
- Erna Arngrímsdóttir – varamaður í stjórn
- Sigrún Dóra Hemmert – varamaður í stjórn





Kærar þakkir fyrir daginn

